Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioscience
Dreier LLP Announces Class Action Lawsuit Against Neurocrine Biosciences, Inc.(NBIX)
July 10th, 2007
Dreier LLP announces that a class action lawsuit was commenced in the United States District Court for the Southern District of California, on behalf of purchasers of the common stock of Neurocrine Biosciences, Inc. ("Neurocrine" or the "Company") (NASDAQ:NBIX) during the period June 20, 2002 through June 23, 2006, inclusive (the "Class Period"). The complaint alleges violations of the federal securities laws, including Section 10(b) of the Securities Exchange Act of 1934. If you purchased Neurocrine common stock during the Class Period, you may be a member of the proposed Class. You must move the Court on or before August 20, 2007 if you...
Source: Drug Law Weekly (2007-07-10)
|
